Healthcare costs for metastatic castration-resistant prostate cancer patients treated with Abiraterone or Enzalutamide

Rana, D. et al. (2021) Healthcare costs for metastatic castration-resistant prostate cancer patients treated with Abiraterone or Enzalutamide. PharmacoEconomics, (Accepted for Publication)

[img] Text
256032.pdf - Accepted Version
Restricted to Repository staff only

2MB

Item Type:Articles
Status:Accepted for Publication
Refereed:Yes
Glasgow Author(s) Enlighten ID:Rana, Miss Dikshyanta and Geue, Dr Claudia
Authors: Rana, D., Geue, C., Baillie, K., Pan, J., Mueller, T., Laskey, J., Bennie, M., Clarke, J., Jones, R. J., Brown, A., and Wu, O.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Health Economics and Health Technology Assessment
Journal Name:PharmacoEconomics
Publisher:Springer
ISSN:1170-7690
ISSN (Online):1179-2027

University Staff: Request a correction | Enlighten Editors: Update this record